PMID- 35634698
OWN - NLM
STAT- MEDLINE
DCOM- 20220602
LR  - 20220607
IS  - 1531-698X (Electronic)
IS  - 1040-8703 (Linking)
VI  - 34
IP  - 3
DP  - 2022 Jun 1
TI  - Bivalirudin in pediatric extracorporeal membrane oxygenation.
PG  - 255-260
LID - 10.1097/MOP.0000000000001131 [doi]
AB  - PURPOSE OF REVIEW: This review summarizes the current literature surrounding the 
      use of bivalirudin as an alternative anticoagulant for pediatric extracorporeal 
      membrane oxygenation (ECMO) patients. RECENT FINDINGS: Recent single center 
      studies describe that bivalirudin may be associated with decreased blood product 
      transfusion, decreased cost and similar clinical outcomes for pediatric ECMO 
      patients who have failed unfractionated heparin (UFH) anticoagulation. aPTT is 
      the most common test to monitor bivalirudin but has several limitations. Other 
      tests including dilute thrombin time (dTT) and viscoelastic assays are promising 
      but more study is needed. Current evidence suggests that bivalirudin is a well 
      tolerated and effective alternative anticoagulant for pediatric ECMO patients who 
      have failed UFH anticoagulation but prospective studies are needed to confirm 
      these results. SUMMARY: Bivalirudin is a promising alternative anticoagulant for 
      pediatric ECMO patients who have failed UFH. Large prospective, multicenter 
      studies are needed to confirm safety and efficacy.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Ryerson, Lindsay M
AU  - Ryerson LM
AD  - University of Alberta, Edmonton, Alberta, Canada.
FAU - McMichael, Ali B V
AU  - McMichael ABV
AD  - UT Southwestern, Dallas, Texas, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Pediatr
JT  - Current opinion in pediatrics
JID - 9000850
RN  - 0 (Anticoagulants)
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
MH  - Anticoagulants/adverse effects
MH  - Child
MH  - *Extracorporeal Membrane Oxygenation/methods
MH  - Heparin/adverse effects/therapeutic use
MH  - Hirudins
MH  - Humans
MH  - Peptide Fragments
MH  - Prospective Studies
MH  - Recombinant Proteins
EDAT- 2022/06/01 06:00
MHDA- 2022/06/03 06:00
CRDT- 2022/05/31 10:10
PHST- 2022/05/31 10:10 [entrez]
PHST- 2022/06/01 06:00 [pubmed]
PHST- 2022/06/03 06:00 [medline]
AID - 00008480-202206000-00002 [pii]
AID - 10.1097/MOP.0000000000001131 [doi]
PST - ppublish
SO  - Curr Opin Pediatr. 2022 Jun 1;34(3):255-260. doi: 10.1097/MOP.0000000000001131.